natgillin/translations-raw huggingface dataset:
Active-Controlled, 4-Week, Noninferiority, Blinded Crossover Study (Study 1) A randomised, double-blind, active-controlled, crossover, noninferiority study (Study 1) compared equivalent doses of glycerol phenylbutyrate to sodium phenylbutyrate by evaluating 24-hour venous ammonia levels in patients with UCDs who had been on sodium phenylbutyrate prior to enrolment for control of their UCD.
Z zdravilno učinkovino kontrolirana, 4-tedenska, prednostna, slepa, navzkrižna študija (Študija 1) Randomizirana, dvojno slepa, z aktivno učinkovino kontrolirana, navzkrižna študija neinferiornosti (Študija 1) je primerjala enake odmerke glicerol fenilbutirata z natrijevim fenilbutiratom z ocenjevanjem koncentracij amoniaka v krvi v 24 urah pri bolnikih z motnjami ciklusa sečnine, ki so bili zdravljeni z natrijevim fenilbutiratom pred vključitvijo v skupino za nadzorovanje njihove motnje ciklusa sečnine.
Do not re-use the oral syringe for measuring the dose of RAVICTI on another day.
Peroralne brizge drug dan ne smete ponovno uporabiti za odmerjanje zdravila RAVICTI.
Tell a doctor straight away if: • you are sick (vomit), which is a common side effect, more than once and this does not stop.
• če bruhate (kar je pogost neželeni učinek) več kot enkrat in slabost ne preneha.
The incidence of the following tumours was also increased in female rats: thyroid follicular cell adenoma, carcinoma and combined adenoma or carcinoma, adrenal cortical combined adenoma or carcinoma, cervical schwannoma, uterine endometrial stromal polyp, and combined polyp or sarcoma.
Pojavnost naslednjih tumorjev je prav tako narasla pri samicah podgan: folikularni adenomi ščitnice, karcinomi in kombinirani adenomi ali karcinomi, adenom skorje nadledvične žleze ali karcinom skorje nadledvične žleze, cervikalni švanom, maternični endometrijski stromalni polip in kombiniran polip ali sarkom.
In healthy subjects, after administration of 4 ml, 6 ml, and 9 ml 3 times daily for 3 days, the ratio of mean AUC0-23h of PAA to PAGN was 1, 1.25, and 1.6, respectively.
Pri zdravih preiskovancih je bilo po aplikaciji 4 ml, 6 ml in 9 ml trikrat na dan razmerje med srednjimi vrednostmi AUC0-23h PAA in PAGN 1, 1,25 in 1,6.
The bottle is packed with a reclosable bottle cap adapter.
Steklenica je pakirana z zamaškom z nastavkom za brizgo.
In vitro studies evaluating the percent recovery of total dose delivered with nasogastric or gastrostomy tubes demonstrated the percent of dose recovered was >99% for doses > 1 ml and 70% for a 0.5 ml dose.
Študije in vitro, ki so ocenjevale odstotek izkoriščenega odmerka pri skupnem odmerku, dostavljenem prek nazogastričnih sond ali gastrostome, so pokazale, da je izkoriščeni odmerek > 99 % za odmerke > 1 ml in 70 % za odmerek 0,5 ml.
Metrorrhagia Uncommon Amenorrhoea, irregular menstruation
Izostanek menstruacije, neredna menstruacija
In a separate study, in patients with hepatic impairment (Child-Pugh B and C), the ratios of mean values for PAA to PAGN among all patients dosed with 6 ml and 9 ml twice daily ranged from 0.96 to 1.28 and for patients dosed with 9 ml twice daily ranged from 1.18-3.19.
V ločeni študiji pri bolnikih z okvaro jeter (Child-Pugh razred B in C) so bila razmerja med srednjimi vrednostmi PAA in PAGN med vsemi bolniki z odmerki 6 ml in 9 ml dvakrat na dan od 0,96 do 1,28 in pri bolnikih z odmerkom 9 ml dvakrat na dan od 1,18 do 3,19.
• tests show higher triglycerides, low density lipo-protein or white cells in your blood
• preiskave, ki kažejo povišane vrednosti trigliceridov, zvišane vrednosti lipoproteinov majhne gostote ali belih krvnih celic
• lipase inhibitors - used to treat obesity
• zaviralci lipaze - uporabljajo se za zdravljenje debelosti
Any adverse reaction reported in one patient met the uncommon criteria.
Vsak neželeni učinek, ki se je pojavil pri enem bolniku, se šteje kot občasen.
• Total daily dosage of RAVICTI (ml) = total daily dosage of sodium phenylbutyrate tablets (g) x
• Skupni dnevni odmerek zdravila RAVICTI (ml) = skupni odmerek tablet natrijevega fenilbutirata (g) x 0,86
Assay sensitivity was confirmed by significant QTc prolongation of the positive control, moxifloxacin.
Občutljivost analize je bila potrjena s pomembnim podaljšanjem intervala QTc pri uporabi pozitivne kontrole,
Use an oral syringe to measure your dose.
Za merjenje odmerka uporabite peroralno brizgo.
PBA derived from glycerol phenylbutyrate is further converted by β-oxidation to PAA.
PBA, ki nastane iz glicerol fenilbutirata, se nadalje pretvori v PAA z β-oksidacijo.
Following 4 ml of glycerol phenylbutyrate for 3 days (3 times a day [TID]), mean Cmax and AUC were 66 mcg/ml and 930 mcg•h/ml for PBA and 28 microgram /ml and 942 mcg•h/ml for PAA,
Po prejetju 4 ml glicerol fenilbutirata 3 dni zapored (3-krat na dan) sta bili srednji vrednosti Cmax in AUC 66 μg/ml in 930 μg g•h/ml za PBA ter 28 mikrogramov /ml in 942 μg•h/ml za PAA.
In a study in patients with clinically decompensated cirrhosis and hepatic encephalopathy (Child-Pugh B and C), mean Cmax of PAA was 144 mcg/ml (range: 14-358 mcg /ml) after daily dosing of 6 ml of glycerol phenylbutyrate twice daily, while mean Cmax of PAA was 292 mcg /ml (range: 57-655 mcg/ml) after daily dosing of 9 ml of glycerol phenylbutyrate twice daily.
V študiji z bolniki s klinično dekompenzirano cirozo in jetrno encefalopatijo (Child-Pugh razred B in C), je bila povprečna vrednost Cmax pri PAA 144 μg/ml (razpon: 14-358 μg/ml) po dnevnem odmerku 6 ml glicerol fenilbutirata dvakrat na dan, medtem ko je bila povprečna vrednost Cmax PAA 292 μg /ml (razpon: 57-655 μg/ml) po dnevnem odmerku 9 ml glicerol fenilbutirata dvakrat na dan.
Open-Label, Uncontrolled, Extension Studies in Paediatric Patients Long-term (12-month), uncontrolled, open-label studies were conducted to assess monthly ammonia control and hyperammonaemic crisis over a 12-month period in three studies (Study 2, which also enrolled adults, and extensions of Studies 3 and 4).
Odprta, nenadzorovana podaljšana pediatrična študija Za ocenjevanje mesečnega nadzora ravni amoniaka in hiperamoniemične krize v obdobju 12 mesecev so bile v treh študijah opravljene dolgoročne (12-mesečne), nenadzorovane, odprte študije (Študija 2, ki je vključevala tudi odrasle, ter podaljška Študij 3 in 4).
Concomitant use of medicinal products known to inhibit lipase should be given with caution as glycerol phenylbutyrate is hydrolysed by digestive lipase into phenylbutyrate acid and glycerol.
Sočasna uporaba zdravil, za katera je znano, da zavirajo lipazo, je treba dajati previdno ob upoštevanju, da se glicerol fenilbutirat v prebavilih hidrolizira z lipazo v fenilbutirično kislino in glicerol.
Glycerol phenylbutyrate and/or its metabolites, PAA and PBA, have been shown to be weak inducers of CYP3A4 enzyme in vivo.
Glicerol fenilbutirat in/ali njegova presnovka, PAA in PBA, so znani kot šibki induktorji encima CYP3A4 v pogojih in vivo.
Women of childbearing potential/contraception in males and females Effective contraceptive measures must be taken by women of child-bearing potential (see section 4.6).
Ženske v rodni dobi/kontracepcija pri moških in ženskah Ženske v rodni dobi morajo uporabljati učinkovito obliko kontracepcije (glejte poglavje 4.6)
If there is a need to administer a dose of 0.5 ml or less with such nasogastric, gastrostomy or nasojejunal tubes, consideration should be given to the low drug recovery in dosing.
Če je treba aplicirati odmerek 0,5 ml ali manj preko nazogastrične sonde, gastrostome ali nazojejunalne sonde, je treba pri odmerjanju upoštevati nizek odstotek izkoristka zdravila.
Uncommon Ventricular arrhythmia
Ventrikularna aritmija
However, for adults, if the next dose is in less than 2 hours, then skip it and take your next dose as normal.
Za odrasle: če je naslednji odmerek na vrsti v manj kot dveh urah, pozabljeni odmerek izpustite.
RAVICTI and meals
Zdravilo RAVICTI in obroki
• The active substance is glycerol phenylbutyrate.
• Učinkovina je glicerol fenilbutirat.
• burping, stomach ache, changes in your stools such as being oily, urgent need for bowel movements, painful bowel movements
• spahovanje, bolečine v trebuhu, spremembe pri blatu, npr. oljnato blato, nujna potreba po odvajanju blata, boleče odvajanje blata
In an additional long term (24 month), uncontrolled, open-label clinical study the safety of RAVICTI has been evaluated in 16 UCD patients less than 2 months of age and 10 pediatric patients with UCDs aged 2 months to less than 2 years.
Poleg dolgoročne (24-mesečne), nenadzorovane, odprte klinične študije so varnost zdravila RAVICTI ocenili pri 16 bolnikih z UCD, starih manj kot 2 meseca, in pri 10 pediatričnih bolnikih z UCD, starih
Mean blood glutamine levels were also non-significantly lower after glycerol phenylbutyrate treatment compared with sodium phenylbutyrate treatment by -45.2 ± 142.94 micromol/L (p = 0.135, paired ttest; p = 0.114, Wilcoxon signed-rank test).
Srednje vrednosti glutamina v krvi so bile prav tako statistično neznačilno nižje po zdravljenju z glicerol fenilbutiratom v primerjavi z natrijevim fenilbutiratom - za -45,2 ± 142,94 mikromol/l (p = 0,135, parni t-test; p = 0,114, Wilcoxonov preizkus predznačenih rangov).
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING 25 ml BOTTLE LABEL
PODATKI NA PRIMARNI OVOJNINI NALEPKANA 25 ml STEKLENICI
In 7 paediatric patients aged 2 months to under 2 years of age who received RAVICTI for up to 12 months, the concentrations of PAA, PBA, and PAGN did not increase over the treatment period and the overall median PAA, PBA, and PAGN concentrations in these patients were similar to those observed in older paediatric age groups.
Pri 16 pediatričnih bolnikih z UCD, starih manj kot 2 meseca, je bil očistek PAA 3,8 l/h Pri 7 pediatričnih bolnikih, starih 2 meseca do manj kot 2 leti, ki so prejemali zdravilo RAVICTI do 12 mesecev, se koncentracije PAA, PBA in PAGN niso zvišale v času zdravljenja; na splošno so bile mediane vrednosti koncentracij PAA, PBA in PAGN pri teh bolnikih podobne tistim, ki so bile opažene pri starejših pediatričnih skupinah.
Important note: Do not add or stir RAVICTI into larger volumes of liquid such as water or juice as the introduction of water causes glycerol phenylbutyrate to degrade.
Pomembno opozorilo: Ne dodajajte in ne mešajte zdravila RAVICTI v večje količine tekočin, kot so voda ali sok, ker dodatek vode povzroči razpad glicerol fenilbutirata.
In healthy subjects, intact glycerol phenylbutyrate was not detected in plasma.
Pri zdravih preiskovancih intaktnega glicerol fenilbutirata v plazmi niso odkrili.
Date of first authorisation: 27 November 2015
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM EU/1/15/1062/001 DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 27. november 2015
Of 51 adult patients participating in Study 2, 7 patients (14%) reported a total of 10 hyperammonaemic crises during treatment with glycerol phenylbutyrate as compared with 9 patients (18 %) who had reported a total of 15 crises in the 12 months prior to study entry while they were being treated with sodium phenylbutyrate.
Od 51 odraslih bolnikov, ki so sodelovali v Študiji 2, je 7 bolnikov (14 %) poročalo o skupno 10 hiperamoniemičnih krizah v času zdravljenja z glicerol fenilbutiratom, v primerjavi z 9 bolniki (18 %), ki so poročali o skupno 15 krizah pri zdravljenju z natrijevim fenilbutiratom v obdobju 12 mesecev pred vključitvijo v študijo.
• feeling hungry, weight loss or weight gain
• občutek lakote, izguba telesne mase, pridobivanje telesne mase
In the same study, following 6 ml of glycerol phenylbutyrate for 3 days (TID), mean Cmax and AUC were 100 mcg/ml and 1400 mcg•h/ml for PBA and 65 mcg/ml and 2064 mcg•h/ml for PAA, respectively.
V isti študiji je bila po prejetju 6 ml glicerol fenibutirata 3 dni zapored povprečna vrednost Cmax in AUC 100 μg/ml in 1400 μg g•h/ml za PBA ter 65 mikrogramov /ml in 2064 μg•h/ml za PAA.
If you notice any of the following signs, talk to a doctor or go to a hospital straight away as these may be signs of overdose or high ammonia:
Če opazite katerega koli od naslednjih znakov, se pogovorite z zdravnikom ali takoj poiščite pomoč v najbližji bolnišnici, saj so to lahko znaki prevelikega odmerjanja ali visoke koncentracije amoniaka: • občutek zaspanosti, utrujenosti, omotičnosti ali včasih zmedenosti
RAVICTI is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
Zdravilo RAVICTI je indicirano za uporabo kot dodatno zdravilo za dolgoročno obravnavanje bolnikov z motnjami ciklusa sečnine (UCD, urea cycle disorder), vključno s pomanjkanjem karbamoilfosfat sintetaze I (CPS, carbamoyl phosphate synthetase), ornitin karbamoiltransferaze (OTC, ornithine carbamoyltransferase), argininosukcinat sintetaze (ASS), argininosukcinat liaze (ASL), arginaze I (ARG), in pomanjkanje ornitin translokaze (sindrom hiperornitinemijahiperamonemija-homocitrulinurija (HHH)), ki jih ni mogoče zdraviti samo s posebno dieto z malo beljakovinami in/ali dodatkom aminokislin.
The UCDs include deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH).
Motnje ciklusa sečnine vključujejo pomanjkanje karbamoilfosfat sintetaze I (CPS, carbamoyl phosphate-synthetase-I), ornitin karbamoiltransferaze (OTC, ornithine carbamoyltransferase), argininosukcinat sintetaze (ASS), argininosukcinat liaze (ASL), arginaze I (ARG) in pomanjkanje ornitin translokaze (sindrom hiperornitinemija-hiperamonemija-homocitrulinurija (HHH)).
Based on prescribed dosing volume, patients should be advised to obtain CE marked oral syringes with suitable size for the dosage and compatible with the reclosable bottle cap adapter from the pharmacy.
Na podlagi predpisanega volumna odmerka je treba bolnikom svetovati, da v lekarni dobijo peroralne brizge z oznako CE, ki so primerne velikosti za predpisani odmerek in združljive z zamaški z nastavkom za brizgo.
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking RAVICTI.
Če karkoli od naštetega velja za vas (ali pa niste prepričani), se pogovorite z zdravnikom ali farmacevtom, preden vzamete zdravilo RAVICTI.
• through a tube that goes through your tummy (‘abdomen') to the stomach - called a
• skozi cevko, ki gre skozi vaš trebuh do želodca - gastrostoma
About urea cycle disorders
O motnjah ciklusa sečnine
The efficacy of glycerol phenylbutyrate in paediatric patients 2 months to 17 years of age involving deficiencies of OTC, ASS, ASL, and ARG was evaluated in 2 fixed sequence, open-label, sodium phenylbutyrate to equivalent dosing of glycerol phenylbutyrate switchover studies (Studies 3 and 4).
Klinične študije pri otrocih z motnjami ciklusa sečnine Učinkovitost glicerol fenilbutirata pri pediatričnih bolnikih, starih od 2 mesecev do 17 let z okvarami OTC, ASS, ASL in ARG so ocenjevali v dveh odprtih študijah prehoda s fiksnim zaporedjem, ki sta primerjali natrijev fenilbutirat z enakovrednimi odmerki glicerol fenilbutirata (Študija 3 in 4).
Population pharmacokinetic modelling and dosing simulations suggest that PBA enters the circulation about 70-75% more slowly when given orally as glycerol phenylbutyrate as compared with sodium phenylbutyrate and further indicate that body surface area is the most significant covariate explaining the variability of PAA clearance.
Farmakokinetično modeliranje in simulacije odmerkov v populaciji nakazujeta, da PBA vstopi v krvni obtok približno 70-75 % počasneje, kadar je peroralno zaužit kot glicerol fenilbutirat, v primerjavi z natrijevim fenilbutiratom.
• You should have the medicine with the reclosable bottle cap adapter along with an oral syringe to administer the correct amount of glycerol phenylbutyrate.
• Imeti morate zdravilo z zamaškom z nastavkom za brizgo in peroralno brizgo, za lažjo aplikacijo ustrezne količine glicerol fenilbutirata.
• 7 ml/m2/day (8 g/m2/day) in patients with a BSA ≥ 1.3 m2
• 7 ml/m2/na dan (8 g/m2/na dan) za bolnike s telesno površino ≥ 1,3 m2
• 8.5 ml/m2/day (9.4 g/m2/day) in patients with a body surface area (BSA) < 1.3 m2
• 8,5 ml/m2/na dan (9,4 g/m2/na dan) za bolnike s telesno površino < 1,3 m2
In adult UCD patients receiving multiple doses of glycerol phenylbutyrate, maximum plasma concentrations at steady state (Cmaxss) of PBA, PAA, and PAGN occurred at 8 h, 12 h, and 10 h, respectively, after the first dose in the day.
Pri odraslih z UCD, ki so prejemali večkratne odmerke glicerol fenilbutirata, se je najvišja vrednost plazemske koncentracije ob stanju dinamičnega ravnovesja (Cmaxss) PBA, PAA in PAGN pojavila po 8, 12 in 10 urah po prvem dnevnem odmerku.
Reduced phenylbutyrate absorption in pancreatic insufficiency or intestinal malabsorption Exocrine pancreatic enzymes hydrolyse glycerol phenylbutyrate in the small intestine, separating the active moiety, phenylbutyrate, from glycerol.
Zmanjšana absorpcija fenilbutirata pri pankreatični insuficienci ali črevesni malabsorpciji Eksokrini encimi trebušne slinavke hidrolizirajo glicerol fenilbutirat v tankem črevesu in ločijo aktivno molekulo, fenilbutirat, od glicerola.
Additional side effects in children less than 2 months of age
Dodatni neželeni učinki pri otrocih, starih manj kot 2 meseca
The same reclosable bottle cap adapter can be used until a bottle is empty.
Isti zamašek z nastavkom za brizgo injekcijske brizge se lahko uporablja, dokler ni vsebina steklenice prazna.
In healthy, fasting adult subjects receiving a single oral dose of 2.9 ml/m2 of glycerol phenylbutyrate, peak plasma levels of PBA, PAA, and PAGN occurred at 2 h, 4 h, and 4 h, respectively.
Pri zdravih odraslih preiskovancih na tešče, ki prejemajo enkratni peroralni odmerek 2,9 ml/m2 glicerol fenilbutirata, so bile najvišje vrednosti koncentracij PBA, PAA in PAGN dosežene po 2, 4 oz. 4 urah.
RAVICTI 1.1 g/ml oral liquid Glycerol phenylbutyrate
RAVICTI 1,1 g/ml peroralna tekočina glicerol fenilbutirat
Tabulated list of adverse reactions The adverse reactions are listed below, by system organ class and by frequency.
Neželeni učinki so navedeni spodaj glede na organski sistem in pogostost.
Of the 49 paediatric patients who participated in these extension studies, 12 patients (25 %) reported a total of 17 hyperammonaemic crises during treatment with glycerol phenylbutyrate as compared with 38 crises in 21 patients (43 %) in the preceding 12 months prior to study entry, while they were being treated with sodium phenylbutyrate.
Od 49 otrok, ki so sodelovali v teh podaljšanih študijah, je 12 bolnikov (25 %) poročalo o skupno 17 hiperamoniemičnih krizah v času zdravljenja z glicerol fenilbutiratom, v primerjavi z 21 bolniki (43 %), ki so poročali o skupno 38 krizah pri zdravljenju z natrijevim fenilbutiratom v obdobju 12 mesecev pred vključitvijo v študijo.
The product contains no excipients.
Zdravilo ne vsebuje pomožnih snovi.
How to take RAVICTI
Kako jemati zdravilo RAVICTI
Amino acid level decreased Gamma-glutamyltransferase increased Hepatic enzyme increased Transaminases increased
Zmanjšana raven aminokisline Zvišana raven gama-glutamiltransferaze Zvišana raven jetrnega encima Zvišana raven transaminaz
Therefore, therapeutic effects and/or metabolite levels of medicinal products, including some oral contraceptives, that are substrates for this enzyme may be reduced and their full effects cannot be guaranteed, following coadministration with glycerol phenylbutyrate.
Zato se po sočasni aplikaciji glicerol fenilbutirata terapevtski učinki in/ali ravni presnovkov zdravila, vključno z nekaterimi peroralnimi kontraceptivi, ki so substrati za ta encim, lahko znižajo in njihov polni učinek ni zagotovljen.
Three patients were treatment naïve and three additional patients were gradually discontinued from intravenous sodium benzoate and sodium phenylacetate while RAVICTI was initiated.
Trije bolniki predhodno še niso bili zdravljeni, pri treh dodatnih bolnikih pa so postopoma prekinjali intravensko dajanje natrijevega benzoata in natrijevega fenilacetata, medtem ko so uvajali zdravilo RAVICTI.
Consistent with plasma ammonia, blood glutamine levels were lower during glycerol phenylbutyrate treatment as compared with sodium phenylbutyrate in each arm of the crossover study (decrease of 44.3 ± 154.43 micromol/L after glycerol phenylbutyrate compared with NaPBA; p = 0.064, paired t-test; p = 0.048, Wilcoxon signed-rank test).
Skladno s plazemsko koncentracijo amoniaka so bile ravni glutamina v krvi nižje v času zdravljenja z glicerol fenilbutiratom v primerjavi z natrijevim fenilbutiratom v vsakem terapevtskem kraku navzkrižne študije (upad za 44,3 ± 154,43 mikromol/l po aplikaciji glicerol fenilbutirata v primerjavi z natrijevim fenilbutiratom; p = 0,064, parni t-test; p = 0,048, Wilcoxonov preizkus predznačenih rangov).
RAVICTI must be used with dietary protein restriction and sometimes dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements) depending on the daily dietary protein intake needed to promote growth and development.
Zdravilo RAVICTI se uporablja skupaj s posebno dieto z malo beljakovinami in v nekaterih primerih skupaj s prehranskimi dodatki (npr. esencialne aminokisline, arginin, citrulin, kalorični dodatki brez beljakovin) glede na dnevni vnos prehranskih beljakovin, ki so potrebne za pospeševanje rasti in razvoja.
Women of childbearing potential/contraception in males and females The use of RAVICTI in women of childbearing potential must be accompanied by the use of effective contraception (see section 4.4).
Ženske v rodni dobi/kontracepcija pri moških in ženskah Zdravilo RAVICTI je treba pri ženskah v rodni dobi uporabljati sočasno z učinkovito kontracepcijo (glejte poglavje 4.4).
The dose of glycerol phenylbutyrate should be adjusted to produce a fasting plasma ammonia level that is less than half the upper limit of normal (ULN) in patients 6 years and older.
Odmerek glicerol fenilbutirata je treba prilagoditi, da pri bolnikih, starih 6 let in več, raven plazemskega amoniaka na tešče ostane pod polovico zgornje meje normalne vrednosti (ULN - upper limit of normal).
• if you have acute hyperammonaemia, which requires more rapid intervention.
• če ste alergični na glicerol fenilbutirat • če imate akutno hiperamoniemijo, ki zahteva hitro ukrepanje.
What RAVICTI is and what it is used for What you need to know before you take RAVICTI How to take RAVICTI
Kaj morate vedeti, preden boste vzeli zdravilo RAVICTI Kako morate jemati zdravilo RAVICTI
Two patients were treatment naïve and one additional patient was gradually discontinued from intravenous sodium benzoate and sodium phenylacetate while RAVICTI was initiated.
Dva bolnika predhodno še nista bila zdravljena, pri enem dodatnem bolniku pa so postopoma prekinjali intravensko dajanje natrijevega benzoata in natrijevega fenilacetata, medtem ko so uvajali zdravilo RAVICTI.
A total of 49 children ages 2 months to 17 years with deficiencies of OTC, ASS, ASL, and ARG were enrolled, and all but 1 had been converted from sodium phenylbutyrate to glycerol phenylbutyrate.
Skupno 49 otrok, starih od 2 mesecev do 17 let, z okvarami OTC, ASS, ASL in ARG je bilo vključenih v študije in vsi razen enega so prešli z natrijevega fenilbutirata na glicerol fenilbutirat.
Uncommon Back pain, joint swelling, muscle spasm, pain in extremity, plantar fasciitis
Bolečine v hrbtu, otekanje sklepov, krči mišic, bolečina v okončinah, plantarni fasciitis
Hypophagia
Hipotiroidizem